NASDAQ:ADROAduro BioTech Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aduro BioTech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.57 -0.80 (-23.74 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$2.55Now: $2.57▼$3.4350-Day Range$2.69MA: $3.04▼$3.3752-Week Range$0.90Now: $2.57▼$4.04Volume2.76 million shsAverage Volume440,783 shsMarket Capitalization$207.76 millionP/E RatioN/ADividend YieldN/ABeta0.35 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingAduro BioTech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Aduro BioTech has a potential upside of 114.0% from its current price of $2.57.Amount of Analyst CoverageAduro BioTech has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesAduro BioTech has received 454 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAduro BioTech has received 272 “underperform” votes. (Add your “underperform” vote.)Community SentimentAduro BioTech has received 62.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aduro BioTech and other stocks. Vote “Outperform” if you believe ADRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAduro BioTech does not currently pay a dividend.Dividend GrowthAduro BioTech does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aduro BioTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Aduro BioTech is held by insiders.Percentage Held by Institutions48.14% of the stock of Aduro BioTech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aduro BioTech are expected to grow in the coming year, from ($0.70) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aduro BioTech is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aduro BioTech is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAduro BioTech has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADRO Previous Symbol CUSIPN/A CIK1435049 Webwww.aduro.com Phone510-848-4400Debt Debt-to-Equity Ratio0.52 Current Ratio9.13 Quick Ratio9.13Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.26 million Price / Sales12.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book3.17Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-82,370,000.00 Net Margins-243.93% Return on Equity-86.31% Return on Assets-21.67%Miscellaneous Employees152 Outstanding Shares80,840,000Market Cap$207.76 million Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:ADRO Rates by TradingView Receive ADRO News and Ratings via Email Sign-up to receive the latest news and ratings for ADRO and its competitors with MarketBeat's FREE daily newsletter. Aduro BioTech (NASDAQ:ADRO) Frequently Asked Questions How has Aduro BioTech's stock been impacted by COVID-19 (Coronavirus)? Aduro BioTech's stock was trading at $2.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADRO stock has increased by 8.9% and is now trading at $2.57. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aduro BioTech? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Aduro BioTech. When is Aduro BioTech's next earnings date? Aduro BioTech is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Aduro BioTech. How were Aduro BioTech's earnings last quarter? Aduro BioTech Inc (NASDAQ:ADRO) issued its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The biotechnology company had revenue of $13.95 million for the quarter, compared to the consensus estimate of $8.81 million. Aduro BioTech had a negative net margin of 243.93% and a negative return on equity of 86.31%. View Aduro BioTech's earnings history. What price target have analysts set for ADRO? 6 brokerages have issued 12-month target prices for Aduro BioTech's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Aduro BioTech's share price to reach $5.50 in the next year. This suggests a possible upside of 114.0% from the stock's current price. View analysts' price targets for Aduro BioTech. Has Aduro BioTech been receiving favorable news coverage? Headlines about ADRO stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aduro BioTech earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAduro BioTech. Are investors shorting Aduro BioTech? Aduro BioTech saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,630,000 shares, a decline of 11.1% from the April 30th total of 2,960,000 shares. Based on an average trading volume of 864,000 shares, the days-to-cover ratio is presently 3.0 days. Currently, 4.3% of the company's shares are short sold. View Aduro BioTech's Current Options Chain. Who are some of Aduro BioTech's key competitors? Some companies that are related to Aduro BioTech include Nabriva Therapeutics (NBRV), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Applied Therapeutics (APLT), Enanta Pharmaceuticals (ENTA), Rocket Pharmaceuticals (RCKT), INDIVIOR PLC/S (INVVY), BioXcel Therapeutics (BTAI), MacroGenics (MGNX), Athenex (ATNX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Endo International (ENDP), Rhythm Pharmaceuticals (RYTM) and NextCure (NXTC). View all competitors. What other stocks do shareholders of Aduro BioTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), PTC Therapeutics (PTCT), Amarin (AMRN) and Micron Technology (MU). Who are Aduro BioTech's key executives? Aduro BioTech's management team includes the following people: Mr. Stephen T. Isaacs, Chairman, CEO & Pres (Age 70)Dr. Andrea van Elsas, Chief Scientific Officer (Age 52)Mr. Blaine E. Templeman, Chief Admin. Officer & Chief Legal Officer (Age 53)Ms. Jennifer Lew, Chief Financial Officer (Age 46)Ms. Alexandra Santos, Exec. Director of Corp. Affairs & Investor Relations When did Aduro BioTech IPO? (ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. What is Aduro BioTech's stock symbol? Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO." Who are Aduro BioTech's major shareholders? Aduro BioTech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (6.33%), BlackRock Inc. (5.40%), Baillie Gifford & Co. (5.29%), Ikarian Capital LLC (4.50%), Lord Abbett & CO. LLC (2.09%) and JPMorgan Chase & Co. (1.85%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View institutional ownership trends for Aduro BioTech. Which institutional investors are selling Aduro BioTech stock? ADRO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Assenagon Asset Management S.A., JPMorgan Chase & Co., Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, AXA, Deutsche Bank AG, and Russell Investments Group Ltd.. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, and Stephen T Isaacs. View insider buying and selling activity for Aduro BioTech. Which institutional investors are buying Aduro BioTech stock? ADRO stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Ikarian Capital LLC, Lord Abbett & CO. LLC, Nuveen Asset Management LLC, Dupont Capital Management Corp, Thrivent Financial for Lutherans, Soleus Capital Management L.P., and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for Aduro BioTech. How do I buy shares of Aduro BioTech? Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aduro BioTech's stock price today? One share of ADRO stock can currently be purchased for approximately $2.57. How big of a company is Aduro BioTech? Aduro BioTech has a market capitalization of $207.76 million and generates $17.26 million in revenue each year. The biotechnology company earns $-82,370,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe. What is Aduro BioTech's official website? The official website for Aduro BioTech is www.aduro.com. How can I contact Aduro BioTech? Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
